0001140361-19-018070.txt : 20191007 0001140361-19-018070.hdr.sgml : 20191007 20191007191518 ACCESSION NUMBER: 0001140361-19-018070 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191007 FILED AS OF DATE: 20191007 DATE AS OF CHANGE: 20191007 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHADE CHRISTIAN S CENTRAL INDEX KEY: 0001214496 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 191141662 MAIL ADDRESS: STREET 1: MEDAREX STREET 2: 707 STATE ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6095104718 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 form4.xml FORM 4 X0306 4 2019-10-07 0001781983 Aprea Therapeutics, Inc. APRE 0001214496 SCHADE CHRISTIAN S 535 BOYLSTON STREET BOSTON MA 02116 true true President & CEO Common Stock 2019-10-07 4 P 0 1000 15 A 1000 I By adult child Common Stock 2019-10-07 4 P 0 1000 15 A 1000 I By adult child Common Stock 2019-10-07 4 P 0 1000 15 A 1000 I By adult child Common Stock 2019-10-07 4 P 0 1000 15 A 1000 I By adult child Common Stock 2019-10-07 4 P 0 1000 15 A 1000 I By adult child Common Stock 2019-10-07 4 P 0 1000 15 A 1000 I By adult child Common Stock 2019-10-07 4 P 0 5000 15 A 5000 I By spouse Common Stock 160 D Stock Option (right to Buy) 15 2019-10-07 4 A 0 306085 0 A 2029-10-02 Common Stock 306085 306085 D The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. /s/ Scott M. Coiante, attorney-in-fact 2019-10-07